Xeris Pharmaceuticals (XERS)
(Delayed Data from NSDQ)
$1.75 USD
+0.05 (2.94%)
Updated Apr 26, 2024 04:00 PM ET
4-Sell of 5 4
D Value A Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
XERS 1.75 +0.05(2.94%)
Will XERS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for XERS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XERS
Strength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?
Xeris Biopharma (XERS) Reports Q4 Loss, Lags Revenue Estimates
XERS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates
Why Xeris (XERS) Might Surprise This Earnings Season
Xeris (XERS) Up on Licensing Deal With Amgen to Develop Tepezza
Other News for XERS
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Xeris Biopharma: Checking-In On One Of My 'Top Ideas'
Xeris gains as Oppenheimer highlights drug technology
ANGI, MLKN and KOD are among after hour movers